The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux

[1]  N. Turner,et al.  Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital , 2022, Breast Cancer Research and Treatment.

[2]  M. Toi,et al.  Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours , 2022, Cancer drug resistance.

[3]  E. El-demerdash,et al.  Effect of atorvastatin on single oral pharmacokinetics and safety of daclatasvir in rats: Emphasis on P-glycoprotein and cytochrome P450. , 2022, Current drug metabolism.

[4]  A. Sahu,et al.  Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery , 2022, Drug metabolism reviews.

[5]  L. Carey,et al.  Targeting brain metastases in breast cancer. , 2021, Cancer treatment reviews.

[6]  H. Rosing,et al.  P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. , 2021, Molecular pharmaceutics.

[7]  C. Kuntner,et al.  Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice , 2021, Pharmaceutics.

[8]  F. Montemurro,et al.  The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer , 2021, Drug design, development and therapy.

[9]  F. Meric-Bernstam,et al.  Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer , 2021, Clinical Cancer Research.

[10]  A. Falcão,et al.  A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. , 2020, International journal of pharmaceutics.

[11]  R. Bose,et al.  Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Elizabeth C. Randall,et al.  Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. , 2020, Clinical breast cancer.

[13]  N. Andratschke,et al.  Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm , 2020, Clinical and Translational Oncology.

[14]  S. Plewa,et al.  The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid , 2019, Investigational New Drugs.

[15]  Tong Liu,et al.  Elucidation of the Differences in Cinobufotalin’s Pharmacokinetics Between Normal and Diethylnitrosamine-Injured Rats: The Role of P-Glycoprotein , 2019, Front. Pharmacol..

[16]  R. Levy,et al.  Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017 , 2018, Drug Metabolism and Disposition.

[17]  Richard L. Nolan,et al.  Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases , 2018, Pharmacological research.

[18]  Bing Yang,et al.  Influence of paeoniflorin and menthol on puerarin transport across MDCK and MDCK‐MDR1 cells as blood–brain barrier in vitro model , 2018, The Journal of pharmacy and pharmacology.

[19]  Qinghai Zhang,et al.  Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. , 2017, Journal of medicinal chemistry.

[20]  Gilberto Alves,et al.  Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors , 2017, Drug Metabolism and Disposition.

[21]  Sung-Bae Kim,et al.  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[22]  E. Deeks.  Neratinib: First Global Approval , 2017, Drugs.

[23]  L. O’Driscoll,et al.  Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4 , 2017, British Journal of Cancer.

[24]  J. Abraham,et al.  Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor. , 2016, Clinical breast cancer.

[25]  F. Theodoulou,et al.  ABC transporter research: going strong 40 years on , 2015, Biochemical Society transactions.

[26]  Yongzhou Hu,et al.  Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models. , 2014, International journal of pharmaceutics.

[27]  A. Palmer,et al.  Overview of Experimental Models of the Blood‐Brain Barrier in CNS Drug Discovery , 2013, Current protocols in pharmacology.

[28]  K. Brouwer,et al.  In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.

[29]  J. Schellens,et al.  Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP , 2012, Investigational New Drugs.

[30]  Donna A Volpe,et al.  Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. , 2011, Future medicinal chemistry.

[31]  B. Hug,et al.  Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. , 2011, British journal of clinical pharmacology.

[32]  W. Tang,et al.  The structure and functions of P-glycoprotein. , 2010, Current medicinal chemistry.

[33]  N. Srinivas.  Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil , 2008, European Journal of Clinical Pharmacology.

[34]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[35]  Ramaswamy Nilakantan,et al.  Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase , 2004, Cancer Research.

[36]  M. Yamazaki,et al.  Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.

[37]  A. Chien,et al.  Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial , 2020 .